**Editorials**

Preventing Deaths from Methotrexate Overdose  
E. Etchells .................................................. 1853

Use of Low-Dose Glucocorticoids and the Risk of Cardiovascular Morbidity and Mortality in Rheumatoid Arthritis: What Is the True Direction of Effect?  
J.M. Davis III, H. Maradit-Kremers, S.E. Gabriel ........................................... 1856

Steroids for Rheumatoid Arthritis: The Honeymoon Revisited (Once Again)  
L. Caplan, A.S. Russell, F. Wolfe .................................................. 1863

Malignancy and Rheumatic Disease — A Real Association?  
S. Chambers, D. Isenberg ........................................... 1866

Bone Mineral Content versus Bone Density in a Population with Osteoarthritis: A New Twist to the Controversy?  
H. McDonald-Blumer .................................................. 1868

ADAM Proteins as Therapeutic Targets in Loosening of Total Hip Replacement Implants?  
S. Naus, J.W. Bartsch .................................................. 1870

Race, Scleroderma, and Survival: Why Is There a Difference?  
M.D. Mayes .................................................. 1873

**Articles**

Household Income and Earnings Losses Among 6,396 Persons with RA  
F. Wolfe, K. Michaud, H.K. Choi, R. Williams .................................................. 1875

Autoimmune Disease Is a Risk Factor for the Development of Non-Hodgkin’s Lymphoma  
J. Cuttner, H. Spiera, K. Troy, S. Wallenstein .................................................. 1884

Demographic and Clinical Factors Associated with In-Hospital Death Among Patients with SSc  

Distinct Expression of Adhesion Molecules on Skin Fibroblasts from Patients with Diffuse and Limited SSc. A Pilot Study  
F. Iannone, M. Matucci-Cerinic, P.C.F. Falappone, S. Guiducci, M. Cinelli, O. Distler, G. Lapadula .................................................. 1893

The Cochrane Review of Physiotherapy Interventions for AS  
H. Dagfinrud, T.K. Kvien, K.B. Hagen .................................................. 1899

IL-1 and NF-κB Polymorphisms in AS in Canada and Korea  
T-H. Kim, M.A. Stone, P. Rahman, et al .................................................. 1907

Etanercept Exerts Beneficial Effects on Articular Cartilage Biomarkers of Degradation and Turnover in Patients with AS  
W.P. Maksymowych, A.R. Poole, L. Hiebert, et al .................................................. 1911

Prevalence, Disease Manifestations, and Treatment of PsA in Western Norway  
T.M. Madland, E.M. Apaiset, A.E. Johannessen, B. Rossebø, J.G. Brun .................................................. 1918

Factors Associated with Musculoskeletal Disability and Chronic Renal Failure in Clinically Diagnosed Primary Gout  
J. Alvarez-Nemegyei, J.C. Cen-Pisté, M. Medina-Escobedo, S. Villanueva-Jorge .................................................. 1923

Clinical Effects of Intraarticular Injection of High Molecular Weight Hyaluronic Acid (Orthovisc®) in OA of the Knee: A Randomized, Controlled, Multicenter Trial  
D. Neustadt, J. Caldwell, M. Bell, J. Wade, J. Gimbel .................................................. 1928

The Genetic Contribution and Relevance of Knee Cartilage Defects: Case-Control and Sib-Pair Studies  
C. Ding, F. Cicuttini, F. Scott, J. Stankovich, H. Cooley, G. Jones .................................................. 1937

Increased Expression and Processing of ADAM 12 (Meltrin-α) in Osteolysis Associated with Aseptic Loosening of Total Hip Replacement Implants  
G. Ma, M. Ainola, M. Liljeström, et al .................................................. 1943

Increased Bone Mineral Content But Not BMD in the Hip in Surgically Treated Knee and Hip OA  
L. Sandini, J.P.A. Arkoiski, J.S. Jurvelin, H. Kröger .................................................. 1951

Comparative Effects of 2 Antioxidants, Selenomethionine and Epigallocatechin-Gallate, on Catabolic and Anabolic Gene Expression of Articular Chondrocytes  

Safety and Tolerability of Oral Daily and Intermittent Ibandronate Are Not Influenced by Age  

Efficacy of Milnacipran in Patients with FM  

**Pediatric Rheumatology**

Eye Findings in Patients with JDM  

Longitudinal Analysis of a Pediatric Rheumatology Clinic Population  
A.M. Rosenberg .................................................. 1992

Contents continued opposite inside back cover . . .
Case Reports

Poststreptococcal Reactive Arthritis with Thoracic Spine Involvement in an Adult
A. Alexopoulou
S.P. Dourakis, N.D. Stamoulis, D. Vassilopoulos, A.J. Archimandritis

Synovial Sarcoma of the Foot Mimicking Acute Gouty Arthritis
Y. Du, S. Pullman-Mooar, H.R. Schumacher

Deaths Following MTX Overdoses by Medical Staff
I. Sinicina, B. Mayr, G. Mall, W. Keil

OMERACT 7

OMERACT 7 International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials, Asilomar, California, USA, May 8-12, 2004

Introduction C.V. Strand, L.S. Simon, P. Tugwell, P. Brooks, M. Boers

Minimal Disease Activity for RA: A Preliminary Definition G.A. Wells, M. Boers, B. Shea, et al

Minimal Clinically Important Difference, Low Disease Activity State, and Patient Acceptable Symptom State: Methodological Issues
F. Tubach, G.A. Wells, P. Ravaud, M. Dougados

Challenges and Progress in Adverse Event Ascertainment and Reporting in Clinical Trials
M.N.D. Lassere, K.R. Johnson, for the OMERACT Drug Safety Working Group

Generic Patient Self-Report and Investigator Report Instruments of Therapeutic Safety and Tolerability
M.N.D. Lassere, K.R. Johnson, S. Van Santen, et al

Standardized Assessment of Adverse Events in Rheumatology Clinical Trials: Summary of the OMERACT 7 Drug Safety Module Update
M.N.D. Lassere, K.R. Johnson, M. Boers, et al


Selection of a Method for Scoring Radiographs for AS Clinical Trials, by the Assessment in AS Working Group and OMERACT D.M.F.M. van der Heijde, R.B.M. Landewé, and the ASAS Working Group


Correspondence

Treating Leukocytoclastic Vasculitis Associated with Etanercept Therapy. Is It Necessary to Stop Etanercept? A. Juan, B. Ribas, C. Nadal, I. Ros

Reply N. Mohan

Letter


Correction

Fibromyalgia Syndrome: Review of Clinical Presentation, Pathogenesis, Outcome Measures, and Treatment P. Mease

Meetings in Rheumatology

Downloaded from www.jrheum.org on April 12, 2017 - Published by The Journal of Rheumatology